Graft-versus-host disease after donor leukocyte infusions: presentation and management
NV Frey, DL Porter - Best practice & research Clinical haematology, 2008 - Elsevier
Donor lymphocyte infusion (DLI) is used after both myeloablative and non-myeloablative
stem-cell transplantation to treat and prevent relapse, to establish full donor chimerism, and
to treat and prevent infections. The major treatment-related complication of DLI is graft-
versus-host disease (GVHD). The presentation and treatment of GVHD after DLI is similar to
its presentation and treatment after stem-cell transplantation, with some notable exceptions.
While GVHD and graft-versus-tumor (GVT) effects are highly correlated after DLI, some …
stem-cell transplantation to treat and prevent relapse, to establish full donor chimerism, and
to treat and prevent infections. The major treatment-related complication of DLI is graft-
versus-host disease (GVHD). The presentation and treatment of GVHD after DLI is similar to
its presentation and treatment after stem-cell transplantation, with some notable exceptions.
While GVHD and graft-versus-tumor (GVT) effects are highly correlated after DLI, some …